Cys-CD36 (139-155)

CAS No. 143257-74-3

Cys-CD36 (139-155)( ——— )

Catalog No. M41919 CAS No. 143257-74-3

CD36 Peptide P (139-155), Cys conjugated is a Cys labelled CD36 Peptide, and can inhibit the immunoadsorption of CD36 by OKM5.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Cys-CD36 (139-155)
  • Note
    Research use only, not for human use.
  • Brief Description
    CD36 Peptide P (139-155), Cys conjugated is a Cys labelled CD36 Peptide, and can inhibit the immunoadsorption of CD36 by OKM5.
  • Description
    CD36 Peptide P (139-155), Cys conjugated is a Cys labelled CD36 Peptide, and can inhibit the immunoadsorption of CD36 by OKM5.
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    143257-74-3
  • Formula Weight
    1977.24
  • Molecular Formula
    C87H133N25O26S
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Leung LL, et al. CD36 peptides enhance or inhibit CD36-thrombospondin binding. A two-step process of ligand-receptor interaction. J Biol Chem. 1992;267(25):18244-18250.?
molnova catalog
related products
  • Cyclamic acid

    Cyclamic acid in the form of its sodium or calcium salt is one of the most widely used artificial sweeteners.

  • Combretol

    Combretol has leishmanicidal activity, it showed moderate activity (growth inhibition 87.3 and 73.0 %, respectively, at 50 μM) against a multidrug-resistant L. tropica line. Combretol also shows weakly active cytotoxic activity.

  • GAC0003A4

    GAC0003A4 is a potent LXR inverse agonist with antitumor activity that inhibits the transcription of LXR proteins.GAC0003A4 degrades LXRβ proteins and inhibits the proliferation of PDAC cells in a dose-dependent manner.